Research On The Innovation Efficiency And Influencing Mechanism Of The Listed Pharmaceutical Companies In China

People’s living conditions is improved and human life expectancy is significantly increased,which make aging has gradually become a worldwide problem.As a country with a high degree of aging,China’s pharmaceutical industry is faced great pressure because of the increasing number of aging and patients.And China’s pharmaceutical enterprises urgently need to make efforts in research activities and carry out high-quality innovation and development to meet the new drug needs brought about by the increasing aging population.Based on this,the innovation efficiency of listed companies in China’s pharmaceutical manufacturing industry is analyzed from the perspective of input and output.And the influence mechanism of innovation activities is explored to provide decision-making support for promoting the high-quality development of China’s pharmaceutical manufacturing industry.The concept of innovation and innovation efficiency are defined.And the innovation theory and innovation system theory are expounded in the paper.Then,the innovation and development status of China’s pharmaceutical manufacturing industry at the overall level and at the level of pharmaceutical listed companies are analyzed.The study shows that the current innovation input and output of China’s pharmaceutical industry are insufficient,and how to improve the innovation output of enterprises,especially to promote the innovation efficiency of China’s pharmaceutical listed companies,has become an urgent problem.Subsequently,this paper uses the combination of nonradial BP-SBM model and Malmquist index model to measure the innovation input-output indicators of 57 pharmaceutical listed companies in China from 2016 to 2020,and explores the change trend of innovation efficiency of pharmaceutical manufacturing companies in China.The results show that from 2016 to 2020,the innovation efficiency of the above 57 sample listed companies only reached24% of the optimal level.The innovation level of pharmaceutical manufacturing industry showed a downward trend overall.The main reason is that more and more listed companies have poor innovation efficiency,which has lowered the level of the entire industry.Among them,the technical efficiency index of 42 listed companies has a restraining effect on total factor productivity.Most of the listed companies’ innovation input does not match the innovation output.And the innovation ability is uneven.On the basis of efficiency analysis,the innovation system dynamics model of Chinese pharmaceutical companies are constructed based on the current situation of the industry and the analysis of the reasons for the innovation efficiency of Chinese pharmaceutical listed companies.The paper uses the real data of Zhejiang Pharmaceutical Co.,Ltd.to carry out simulation experiments,and analyzes the change trend of innovation efficiency of Zhejiang Pharmaceutical Co.,Ltd.under the change of different factors.The results show that with the increase of R&D personnel and R&D capital investment,the number of patent applications has increased year by year,and the main business income and net profit can also maintain stable growth.The innovation efficiency of Zhejiang Pharmaceutical will maintain a stable and small growth from 2020 to 2025.